Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;26(2):93-98.
doi: 10.12793/tcp.2018.26.2.93. Epub 2018 Jun 18.

Population pharmacodynamics of cilostazol in healthy Korean subjects

Affiliations

Population pharmacodynamics of cilostazol in healthy Korean subjects

Yun Seob Jung et al. Transl Clin Pharmacol. 2018 Jun.

Abstract

Cilostazol is used for the treatment of intermittent claudication, ulceration and pain. This study was conducted to develop a population pharmacodynamic (PD) model for cilostazol's closure time (CT) prolongation effect in healthy Korean subjects based on a pharmacokinetic (PK) model previously developed. PD data were obtained from 29 healthy subjects who participated in a study conducted in 2009 at Severance Hospital. The PK model used was a two-compartment model with first order absorption. CT data were best described by a turnover model with a fractional turnover rate constant (Kout ) inhibited by drug effects (Eff), which were represented by a sigmoid Emax model [Eff = Emax · Cγ / (EC 50 γ+Cγ)] with Emax being maximum drug effect, EC 50 drug plasma concentration at 50% of Emax , C drug plasma concentrations, and γ the Hill coefficient. For the selected PD model, parameter estimates were 0.613 hr -1 for Kout , 0.192 for Emax , 730 ng/ml for EC 50 and 5.137 for γ. Sex and caffeine drinking status significantly influenced the baseline CT, which was 85.36 seconds in male non-caffeine drinkers and increased by 15.5% and 16.4% in females and caffeine drinkers, respectively. The model adequately described the time course of CT. This was the first population PD study for cilostazol's CT prolongation effect in a Korean population.

Keywords: Cilostazol; Closure time; Population pharmacodynamic model; Sigmoid Emax model; Turnover model.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: - Authors: The author has no conflict of interest. - Reviewers: Nothing to declare - Editors: Nothing to declare

Figures

Figure 1
Figure 1. Observed cilostazol concentrations and closure times; the solid line represents a smoothed line of concentrations and the dashed line a smoothed line of closure times.
Figure 2
Figure 2. Goodness-of-fit plots for the final PD model; open circles are observations, red lines smoothed lines, and black lines the line of identity (upper panels) and the zero residual line (lower panels).
Figure 3
Figure 3. Visual predictive check for the final PD model; circles represent observed closure times, dashed lines represent 5th, median, and 95th percentiles of predictions, solid lines represent 5th, median, and 95th percentiles of observations, and shaded areas represent 95% confidence intervals of 5th, median, and 95th percentiles of predictions. Time ranges are 0~192 hr in upper panel and 168~192 hr in lower panel, respectively.

References

    1. Horie N, Kaminogo M, lzumo T, Hayashi K, Tsujino A, Nagata I. Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. Neurol Res. 2015;37:619–623. doi: 10.1179/1743132815Y.0000000021. - DOI - PubMed
    1. Falconer TM, Eikelboom JW, Hankey GJ, Norman PE. Management of peripheral arterial disease in the elderly: focus on cilostazol. Clin Interv Aging. 2008;3:17–23. - PMC - PubMed
    1. Chi YW, lavie CJ, Milani RV, White CJ. Safety and efficacy of cilostazol in the management of intermittent claudication. Vasc health Risk Manag. 2008;4:1197–1203. - PMC - PubMed
    1. O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B, Soong CV. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009;49:1226–1234. doi: 10.1016/j.jvs.2008.11.098. - DOI - PubMed
    1. Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol. 1996;314:197–202. - PubMed

LinkOut - more resources